<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00880672</url>
  </required_header>
  <id_info>
    <org_study_id>JHKu1</org_study_id>
    <nct_id>NCT00880672</nct_id>
  </id_info>
  <brief_title>Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate</brief_title>
  <official_title>Apoptosis and Expression of Neovascularization-related Factors in Human Prostate Tissue After Administration of Dutasteride</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Korean Urological Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether dutasteride may influence the expression of
      angiogenesis factors such as hypoxia inducible factor (HIF)-1alpha and vascular endothelial
      growth factor (VEGF) in patients with lower urinary tract symptoms/benign prostatic
      hyperplasia (LUTS/BPH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 41 patients awaiting transurethral resection of the prostate (TURP) will be
      divided into two groups (1:1); twenty patients will receive no medication and 21 will receive
      0.5 mg dutasteride daily for 2 to 4 weeks until TURP. In both groups, the extent, intensity
      and intracellular location of hypoxia inducible factor (HIF)-1alpha and vascular endothelial
      growth factor (VEGF)will be evaluated. Microvessel density will be also compared in the two
      groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIF-1a and VEGF expression</measure>
    <time_frame>2 weeks</time_frame>
    <description>effects of dutasteride on the expression of angiogenesis markers in rat and human prostates</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>dutasteride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral, 5mg, once per day, 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral, 5mg, once per day, 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dutasteride</intervention_name>
    <description>5mg, oral, daily, 2-4 weeks</description>
    <arm_group_label>dutasteride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent

          -  50 years old or older

          -  International Prostate Symptom Score (IPSS) &gt;8

          -  Maximum flow rate (Qmax) &lt;15 ml/s

          -  transurethral resection of the prostate (TURP)

        Exclusion Criteria:

          -  urethral catheter

          -  urinary tract infection (UTI)

          -  liver disease

          -  renal disease

          -  unexplained hematuria

          -  prostate specific antigen (PSA) &gt; 4ng/ml (included if prostate biopsy was negative)

          -  interstitial cystitis

          -  bladder cancer or prostate cancer

          -  pelvic surgery or irradiation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Seung paick, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Urology, Seoul National University Hospital</affiliation>
  </overall_official>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2009</study_first_submitted>
  <study_first_submitted_qc>April 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2009</study_first_posted>
  <last_update_submitted>June 10, 2013</last_update_submitted>
  <last_update_submitted_qc>June 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Ja Hyeon Ku,</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>prostate, dutasteride</keyword>
  <keyword>vascular endothelial growth factor</keyword>
  <keyword>hypoxia inducible factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 7, 2013</submitted>
    <returned>January 23, 2014</returned>
    <submitted>November 18, 2014</submitted>
    <returned>November 25, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

